AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

NCT05602363 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Malignancy
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Waldenstrom Macroglobulinemia
Mantle Cell Lymphoma
Marginal Zone Lymphoma
Follicular Lymphoma
Non-Hodgkin Lymphoma

Interventions

DRUG: Docirbrutinib

Sponsor

Carna Biosciences, Inc.